Teva (NYSE: TEVA) Nears Breakout on a Big Turnaround – Could Rise 40%

Teva Pharmaceutical Industries Limited (NYSE: TEVA) is pressing right up against the top of a rising channel that’s been in place since February — trading within about a dollar of its 52-week high — and looks poised to break out even higher.

As we’ll get to just ahead, the combination of a fresh regulatory win that expands its lineup of lower-cost versions of blockbuster drugs, a financial turnaround that has won back the confidence of all three major credit-rating agencies, and a chart pressing right up against a potential breakout makes TEVA one of the more interesting setups on the board. Here’s what’s going on…

The Themes Behind the Move

Teva is a 125-year-old, Israel-based drugmaker best known as one of the world’s biggest producers of generic medicines — the cheaper, off-patent versions of brand-name drugs sold as tablets, capsules, injectables, inhalers, and creams. Over the past few years, it has been pivoting toward higher-margin branded “innovative” medicines — led by AUSTEDO (for involuntary movement disorders), AJOVY (for migraine prevention), and UZEDY (a long-acting injection for schizophrenia) — plus a growing portfolio of biosimilars.

In plain English, if you’ve ever picked up a low-cost generic prescription at the pharmacy, there’s a decent chance Teva made it. But the story investors are paying for now is different: Teva is transforming from a debt-heavy generics maker fighting price erosion into a leaner company whose growth is driven by its own branded drugs, lower-cost copies of complex biotech drugs, and a pipeline of new FDA decisions.

TEVA’s latest move reflects a powerful confluence of developments — regulatory, commercial, and financial — that have come together in rapid succession over the past four weeks alone to reframe the company’s growth trajectory.

If needed, swipe or scroll sideways to view the full table.

Put it all together, and TEVA is looking less like a debt-heavy generics maker fighting price erosion and more like a re-rated branded-drug growth story — with a restored investment-grade balance sheet, a fast-growing trio of innovative brands, an expanding biosimilar portfolio, and a crowded calendar of FDA decisions on deck.

The story is getting stronger, but the chart is what could determine whether this move has more room to run in the near term. Here are the bullish technical signals traders should be watching now.

Bullish Technical Signals

#1 Uptrend Channel, Pressing the Upper Rail (Daily): Since February, TEVA has climbed inside a well-defined rising channel (purple), stacking higher highs and higher lows with unusual discipline. The lower rail has held on every test. The most telling test came in late July, when price dipped to roughly $30 and reversed right where the channel floor met the rising 200-day SMA, on the heaviest volume in months. That rebound launched a two-month advance that has now carried price to the channel’s upper boundary near $41. To be precise about where things stand: this is not a breakout yet. The upper rail capped rallies in February, May, and again in mid-September, so it is real resistance, and the past two weeks of tight, overlapping candles show buyers and sellers negotiating just beneath it. That is exactly why the setup has two entries. A decisive close above ~$41 would mark the trend accelerating beyond its own slope, while a pullback toward ~$38.70, where the recent consolidation has repeatedly found its footing, offers a lower-risk entry inside the channel. The channel is roughly $8 wide, and projecting that width off a breakout lands in the high-$40s, the same zone as our first target. What to watch for on the break is volume expansion, since the approach to the rail has come on steady rather than surging turnover.

TEVA – Daily Chart

#2 Price Above the 50-Day and 200-Day SMAs (Daily): TEVA trades above both its 50-day SMA ($36.41) and 200-day SMA ($33.54), with the 50-day stacked comfortably above the 200-day in a golden-cross alignment. Both averages slope higher, and the 50-day has visibly steepened since August, which means the intermediate trend is accelerating rather than just persisting. Together they form a tiered support structure. The 50-day is the first line of defense in the mid-$36s. The 200-day sits behind it in the mid-$33s, running just above the channel’s lower rail. The 200-day has already proven itself as the level buyers defended in July, so this support has been tested rather than assumed. Price sits about 9% above the 50-day. That is a healthy cushion for a trending stock rather than an extreme stretch, but it is also why the $38.70 pullback entry is attractive: it narrows the gap without requiring a full retest of the average. The pullback case’s $33.90 stop sits just above the 200-day, so the risk is anchored to the level that actually matters.

#3 ADX and DI Confirm a Strong, Re-Accelerating Trend (Daily): +DI (27.51) sits more than twice as high as –DI (11.77), a spread that leaves no ambiguity about which side controls direction. ADX at 38.95 is well above the 25 threshold, and it sits above both DI lines, the configuration of an established, powerful trend rather than a fledgling one. The sequence behind the current reading is what makes it constructive. ADX eased from a mid-40s peak in late August as the stock consolidated, and it has now turned back up alongside a rebound in +DI while –DI keeps sliding lower. That pattern (trend strength resetting without direction ever flipping, then re-accelerating) is how healthy uptrends breathe. At these levels, ADX is confirming that the trend is durable rather than signaling early innings. The warning sign to watch would be ADX rolling over while +DI and –DI converge, and neither is happening.

#4 RSI Holding the Bullish Range (Daily): RSI reads 59.89, comfortably above the 50 midline. Its range tells you more than that single number. Since the late-July launch, RSI has oscillated between roughly 50 and 70, and every momentum dip has found a floor at the midline. That is the textbook signature of a bull-market regime, where pullbacks in momentum get bought before sellers can take control. The pushes toward 70 in early and late August cooled off without breaking down, and the September dip bottomed just above 50. One honest nuance: RSI is sitting a touch below its signal average (60.72), so short-term momentum is flat. That fits the sideways churn beneath the upper rail and reads as a pause, not a deterioration. With roughly ten points of headroom before overbought, a push through $41 would have room to run before momentum becomes a headwind.

#5 Resistance-Turned-Support at ~$35.96, Above the 50-Week and 200-Week SMAs (Weekly): On the weekly chart, the ~$35.96 level (pink dotted line) capped TEVA twice this year, at the February spike high and again at the May–June range high. The August advance cleared it, the September pullback came back to test it, and it held. Price then pushed on to fresh highs near $41, completing a clean role reversal from ceiling to floor. That support sits well above a steeply rising 50-week SMA ($32.19) and far above the 200-week ($18.40), a golden alignment that keeps the structural uptrend firmly intact. The result is a layered defense: $38.70, then ~$35.96, then the 50-week near $32. This is also where the timeframes agree. The weekly support zone lines up with the daily 50-day and sits above the daily channel floor, so both charts point to the same area as the one the market has chosen to defend. When daily and weekly agree, the signal carries more weight than either would alone.

TEVA – Weekly Chart

#6 MACD Bullish Crossover From Positive Territory (Weekly): The weekly MACD line (2.06) sits above its signal line (1.72), and the histogram (+0.33) has been building for several weeks. The context is what gives this cross its quality. After peaking near 4 in early 2026, MACD spent February through July digesting the prior surge, with the histogram negative as the two lines converged, yet the MACD line never dropped below zero. The fresh crossover therefore fired from positive territory. That makes it a momentum reset within an intact uptrend, a higher-quality continuation signal than a bottom-fishing cross from deep negative levels. The expanding histogram shows the spread between short- and long-term momentum widening, which is the hallmark of re-acceleration. It also mirrors the daily ADX’s reset-and-reaccelerate pattern, so both timeframes are telling the same story.

#7 Aroon Signals a Dominant Uptrend (Weekly): Aroon Up reads 92.86% while Aroon Down sits at 28.57%, a clean bullish configuration with Up above 70 and Down below 30. On the 14-week lookback, those numbers translate precisely. The highest high was set just one week ago, while the lowest low is ten weeks old, dating back to the July trough. Aroon Up has stayed in its upper band since August while Aroon Down has decayed steadily, which means new highs keep arriving as the last low recedes further into the rearview. The wide separation marks an established trend with little internal conflict. Aroon Up is fractionally off its ceiling only because this week has not yet exceeded last week’s high. A weekly close through $41 would reset it to 100 and line up exactly with the daily breakout trigger.

Risks to Consider

Even strong setups can fail, especially in a pharmaceutical turnaround story like Teva. A few things could knock the stock off course:

• A failure to clear the channel’s upper rail near $41 — which has capped rallies in February, May, and September — or a breakdown from the uptrend channel on heavy volume would undermine the bullish thesis
• Negative company-specific news, broader market weakness, or regulatory changes across the pharmaceutical sector could trigger a sell-off
• The olanzapine FDA decision is a genuine binary — a rejection, delay, or restrictive label in Q4 could materially weaken the near-term catalyst story as expectations have risen
• Legacy generics erosion — global generics revenue fell 15% YoY in local currency in Q2 on increased lenalidomide competition, and U.S. generic/biosimilar revenue was down 31% YoY
• Much of the rerating may already be priced in — TEVA closed September 29 at $39.81, just below its $40.79 52-week high and more than double its $18.47 52-week low, and several earlier Street targets around $40–$42 have largely been reached (the ~64× trailing GAAP P/E is distorted by acquisition charges; forward estimates sit around 14×)
• Denosumab biosimilar competition — DEGEVMA enters a crowded market where the FDA has already approved Sandoz’s Wyost as interchangeable with Xgeva, alongside several other denosumab biosimilars, making price erosion and slower share capture plausible
• Pipeline and acquisition execution — more shots on goal also mean more regulatory and clinical failure points, and the Emalex deal drove a $726 million Q2 charge that pushed Teva to a GAAP net loss of $576 million, with approximately $770 million of Emalex-related expense expected in 2026
• Debt and legal overhang — total debt stood at $16.593 billion (net debt of roughly $12.938 billion) at June 30, Teva recorded $230 million of legal settlements and loss contingencies in Q2, and scheduled opioid-settlement payments remain material, even after the court’s September 23 final approval of its third-party-payor opioid settlement
• Insider selling — Director Roberto Mignone sold 367,600 shares at approximately $39.06 on September 18 (roughly $14.36 million), alongside smaller officer sales — though the block represents only about 0.03% of shares outstanding

The Bottom Line

TEVA is pressing against the upper rail of a rising channel on the daily chart while holding above a resistance-turned-support level near $35.96 on the weekly — a dual-timeframe technical setup that historically signals the start of a sustained move higher.

The fundamental story underneath the chart is just as strong: a fresh FDA biosimilar approval, branded-drug sales up 43% to over $1 billion a quarter, and investment-grade ratings restored by all three agencies.

Combine that with multiple regulatory and commercial catalysts staggered through year-end and into 2027 — the olanzapine FDA decision in Q4, Q3 earnings on November 3, the U.S. launches of DEGEVMA and PONLIMSI, a new Phase 2 vitiligo study, and the ecopipam FDA decision in late Q1 2027 — and TEVA looks like one of the more compelling risk-reward setups on the board right now.

If this is a trade you want to get in on, here’s how we’d play it. Below you’ll find our two entry levels — one on a breakout and one on a pullback — both price targets that imply 17%–40% potential upside, and the stop-loss we’re using on each to manage the downside.

Recommended Trade Setup

Because TEVA is pressing right up against the top of its channel rather than clearly through it, we’re offering two ways to play this setup. Both share the same price targets — the difference is how you get in.

Case 1: On Breakout — for traders who want confirmation. This entry only triggers on a decisive move above the channel’s upper rail near $41.

If needed, swipe or scroll sideways to view the full table.

For a risk of approximately $4.00 per share, the target rewards are about $7.00 and $13.00 per share. That makes this roughly a 1:2 and 1:3 risk-reward trade. In other words, the setup offers nearly 2x to 3x more potential upside than downside.

Note on Trade Invalidation: This recommendation stays active as long as the technical structure holds. If TEVA drops to or below the $37.00 stop-loss before the $41.00 entry triggers, the trade is automatically void — the support underpinning the thesis would have broken, and the risk-reward setup would no longer justify entry.

Case 2: On Pullback — for more patient traders. A pullback toward $38.70, where the recent consolidation has repeatedly found its footing, offers a lower entry inside the channel and more upside to the same targets, in exchange for a slightly wider stop.

If needed, swipe or scroll sideways to view the full table.

For a risk of approximately $4.80 per share, the target rewards are about $9.30 and $15.30 per share. That makes this roughly a 1:2 and 1:3 risk-reward trade. In other words, the setup offers nearly 2x to 3x more potential upside than downside.

Keep in mind that the two entries are independent — if TEVA breaks out above $41 without pulling back first, Case 2 may never trigger.

Happy Trading!
Tara and Greg